MY ACCOUNT | NEWSLETTER |

World's First Dog Treats Launched Featuring Calysta’s FeedKind® Pet Protein


Dr. Clauder’s has joined forces with protein pioneer Calysta to launch the world’s first dog treats made with FeedKind® Pet protein, a revolutionary new pet food ingredient.

Announced at the world’s leading pet trade fair, Interzoo, the groundbreaking air-dried treat presented by Dr. Clauder’s makes the most of Calysta’s nutritionally rich protein, which is produced by natural fermentation – making it a perfect non-GMO ingredient that meets market demands for nutritional quality, palatability, and health for pets.

After its debut at Interzoo, the Dr. Clauder Trainee snack cultivated protein treat featuring FeedKind Pet, will be made available for sale in Europe.

FeedKind Pet protein is a fermented ingredient that is nutrient dense, has a complete amino acid profile for dogs, and has postbiotic properties that helps to maintain a healthy gut in animals. Additionally, FeedKind Pet is a vegan protein source.

Herman Sloot, vice president commercial development at Calysta said: “Dog owners have high expectations for their pet’s food and are increasingly conscious about the source, quality, and safety of the ingredients used.

“For the first time, Europe’s pet food sector has the option to choose a high-quality source of protein that is nutritious and kind to the environment. Calysta is now producing at significant scale, and FeedKind Pet is approved for use in pet foods in the EU. We are excited Dr. Clauder’s is introducing a snack featuring FeedKind Pet protein as we set a new standard for dog treats – one that prioritises both taste and health, while looking after our planet.”

Alexander Gerards, Managing partner at Dr. Clauder’s solutions for pets said: ‘’Novel proteins produced with respect for nature, which are vegetarian, nutritious and tasty are well sought after. We are happy that with FeedKind Pet we were able to develop a dog treat that delivers just that: vegetarian, complete amino acid profile and delicious. Dr. Clauder´s Trainee Snack cultivated proteins is a true innovation meeting market demand.”

Alan Shaw, co-founder and CEO of Calysta said: “Pet populations worldwide are rising and there is little indication it will slow any time soon. FeedKind Pet protein is a win-win for both the pet sector and the consumer, offering optimal benefits for pets, owners, and the planet. The first commercial launch of a petfood product in Europe containing FeedKind Pet is an exciting milestone for Calysta.”

About Calysta

Calysta, Inc., San Mateo, CA, is a biotechnology company working towards a future where the world’s growing population has guaranteed food security. Calysta’s aim is to make protein without limits by fermenting low cost, land free carbon sources, to create new feed and food products, creating sustainable, protein ingredients that add to the global food supply.

FeedKind®, protein is made using very little water and no agricultural land by fermenting low cost, land free carbon sources, to create a safe, nutritious, and traceable protein. Produced via a natural fermentation, it is non-GMO, has a complete amino acid profile, and is highly digestible. FeedKind Pet protein is already produced at full commercial scale.

Dr. Clauder’s is a leading brand based in Germany dedicated to pet health, nutrition, and wellness, offering a comprehensive range of high-quality products for dogs and cats. At the ‘dream factory for dogs and cats,” they craft premium pet foods and specialised supplements with high quality ingredients. Dr. Clauder's is trusted by pet owners and professionals for promoting the well-being of dogs and cats.


Source: www.calysta.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Gut Microbiome and Osteoarthritis: Insights From the Naturally Occurring Canine Model of Osteoarthritis

Like0
Dislike0

Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study

Like0
Dislike0

Insights in the Development and Uses of Alternatives to Antibiotic Growth Promoters in Poultry and Swine Production

Like0
Dislike0

Undergrad researchers drive discovery in the College of Veterinary Medicine

Like0
Dislike0

Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top